As of September 5, 2026, the GLP-1 litigation against Eli Lilly (and co-defendant Novo Nordisk) has moved into its most consequential pretrial stage yet. MDL 3094 has grown to well over 3,900 pending gastrointestinal-injury cases as of early August 2026, and the court has scheduled a Rule 702 expert hearing for September 10–18, 2026. This hearing will decide whether plaintiffs’ expert testimony on warnings, preemption, and causation is admissible — a gatekeeping ruling that must happen before any bellwether trial can be scheduled.
No bellwether trial date, settlement, or certified class has been announced. Attorneys continue to file individual injury cases into the MDL rather than a claim form, and monthly status conferences before Judge Karen S. Marston in the Eastern District of Pennsylvania continue through the end of 2026.
Last updated: September 2026
Eli Lilly faces multiple lawsuits in 2026 over its blockbuster drugs Mounjaro, Zepbound, and its insulin products. Thousands of people have filed claims alleging serious side effects, hidden risks, and inflated drug prices.
If you took any Eli Lilly medication and suffered harm, this article covers everything you need. You’ll find the latest case updates, who can file, expected payouts, and key deadlines.
The GLP-1 litigation alone has grown into one of the largest pharmaceutical mass torts in recent memory. Over 10,000 claims are now pending in federal court. That number keeps climbing every month.
Here’s what you should know before the window to file starts closing.
Eli Lilly Lawsuit 2026
The Eli Lilly lawsuit in 2026 refers to several active legal actions targeting the company’s diabetes and weight loss drugs, along with ongoing insulin pricing litigation. These cases span federal and state courts across the country.
The biggest litigation track involves GLP-1 receptor agonist drugs like Mounjaro and Zepbound. Plaintiffs say Eli Lilly knew about severe gastrointestinal side effects but failed to warn patients and doctors properly.
Separately, Eli Lilly still faces claims over insulin pricing. Patients and insurers argue the company artificially inflated the cost of Humalog and Humulin for years.
| Lawsuit Category | Drug Involved | Court | Status in 2026 |
|---|---|---|---|
| GLP-1 Side Effects | Mounjaro, Zepbound | Eastern District of PA (MDL 3094) | Active, bellwether selection underway |
| Insulin Pricing | Humalog, Humulin | Multiple federal and state courts | Some settled, others pending |
| Compounding Dispute | Tirzepatide copies | Federal court | Active litigation |
The year 2026 is shaping up to be a turning point. Bellwether trials could begin, and early settlement talks may start producing real numbers.
Eli Lilly’s legal exposure runs into the billions. Analysts watching the MDL expect activity to accelerate through the summer and fall.
Eli Lilly Lawsuit Update 2026
The most important Eli Lilly lawsuit update for 2026 is the bellwether trial selection process in MDL 3094. This is the federal multidistrict litigation covering GLP-1 drug injury claims.
Judge Gene Pratter in the Eastern District of Pennsylvania oversees this MDL. Her rulings in early 2026 on which cases go to trial first will shape the entire litigation.
Bellwether trials serve as test cases. Think of them like a dress rehearsal. The outcomes help both sides gauge what a jury might do, which often pushes settlement negotiations forward.
Here’s a quick timeline of key developments:
- Late 2024: MDL 3094 officially created for GLP-1 product liability cases
- 2025: Discovery phase, expert witness disclosures, and plaintiff fact sheets filed
- Early 2026: Bellwether case pool narrowed down
- Mid to Late 2026: First bellwether trials expected
On the insulin front, Eli Lilly announced voluntary price cuts in 2023. But several lawsuits argue those cuts came too late and don’t cover past damages.
State attorneys general in multiple states continue pushing their own pricing cases. Those state-level actions could produce separate settlements.
Eli Lilly Class Action Lawsuit
An Eli Lilly class action lawsuit groups many plaintiffs with similar claims into a single case. In 2026, the class action structure applies mainly to the insulin pricing litigation.
The GLP-1 side effects cases are handled differently. Those are individual lawsuits consolidated under the MDL system. Each plaintiff has their own claim but shares pretrial proceedings to save time and resources.
The distinction matters for your potential payout. In a class action, everyone in the class typically gets the same amount. In individual MDL cases, your compensation depends on your specific injuries.
| Feature | Class Action | MDL (Mass Tort) |
|---|---|---|
| Your Own Case | No, grouped together | Yes, individual claims |
| Payout Structure | Same for all class members | Varies by injury severity |
| Control Over Case | Limited | More control |
| Applies To | Insulin pricing claims | GLP-1 side effect claims |
If you overpaid for insulin, you might be part of a class. If you suffered gastroparesis or another severe side effect from Mounjaro or Zepbound, your case is likely individual.
Both paths can lead to compensation. The type of harm you experienced determines which one fits.
Key Takeaway: Eli Lilly faces both class action and individual mass tort claims in 2026, with bellwether trials expected to set the stage for major settlement activity.
Eli Lilly Mounjaro Lawsuit
The Eli Lilly Mounjaro lawsuit centers on claims that the company failed to adequately warn about severe gastrointestinal side effects of tirzepatide. Mounjaro received FDA approval in 2022 for type 2 diabetes.
Plaintiffs allege they developed gastroparesis, pancreatitis, bowel obstruction, and other serious conditions after taking Mounjaro. Many say they would never have used the drug if they had known the true risks.
The FDA’s adverse event reporting system (FAERS) has logged thousands of reports related to Mounjaro. These reports include hospitalizations, emergency surgeries, and cases where patients needed feeding tubes.
Key allegations in the Mounjaro lawsuit include:
- Failure to warn: Eli Lilly allegedly knew about severe GI risks and downplayed them
- Inadequate labeling: The drug’s label did not clearly describe the risk of stomach paralysis
- Aggressive marketing: Promotions focused on weight loss benefits while minimizing dangers
- Manufacturing issues: Some plaintiffs report inconsistent dosing effects
Mounjaro generated over $11 billion in revenue for Eli Lilly in 2024 alone. That financial success is now part of the plaintiffs’ argument. They contend the company prioritized profits over patient safety.
The Mounjaro cases represent the largest share of claims in MDL 3094. Attorneys expect these cases to be front and center during bellwether trials.
Eli Lilly Zepbound Lawsuit
The Eli Lilly Zepbound lawsuit involves the same active ingredient as Mounjaro, tirzepatide, but targets its use as a weight loss drug. Zepbound received FDA approval in November 2023 specifically for chronic weight management.
Plaintiffs in Zepbound cases raise similar allegations to the Mounjaro litigation. They claim Eli Lilly failed to disclose the full scope of gastrointestinal risks associated with tirzepatide.
What makes Zepbound cases unique is the patient population. Many Zepbound users were not diabetic. They took the drug purely for weight loss, which changes the risk-benefit analysis significantly.
A person managing type 2 diabetes might accept certain side effects. Someone using a drug for cosmetic weight loss has a different threshold for acceptable risk.
| Factor | Mounjaro Cases | Zepbound Cases |
|---|---|---|
| FDA Approval | Type 2 Diabetes (2022) | Weight Management (2023) |
| Patient Type | Diabetic patients | Non-diabetic, weight loss users |
| Risk Tolerance | Higher (managing disease) | Lower (elective use) |
| Marketing Focus | Disease management | Lifestyle, appearance |
Zepbound lawsuits argue that Eli Lilly marketed the drug aggressively on social media and through celebrity endorsements. The rapid adoption created a massive user base before long-term safety data was available.
These cases are consolidated alongside Mounjaro claims in MDL 3094. Attorneys handling Zepbound cases say the failure-to-warn claims may actually be stronger given the elective nature of the treatment.
Eli Lilly Insulin Lawsuit
The Eli Lilly insulin lawsuit targets decades of alleged price manipulation of Humalog and Humulin. Patients, insurers, and state governments claim Eli Lilly conspired with pharmacy benefit managers to inflate insulin costs.
At its peak, a single vial of Humalog cost over $300 in the United States. The same insulin sold for a fraction of that price in other countries. For millions of diabetics, insulin is not optional. It is a matter of survival.
Eli Lilly announced a 70% price cut for Humalog in 2023, capping the out-of-pocket cost at $35 per month. But lawsuits argue this voluntary reduction doesn’t erase years of overcharging.
Key facts about the insulin litigation:
- Duration of alleged overcharging: Roughly 2001 to 2023
- Number of affected patients: Estimated in the millions
- Price comparison: U.S. insulin prices were 5 to 10 times higher than in Canada or Europe
- Co-defendants: Novo Nordisk and Sanofi face similar claims
Several state attorneys general have reached settlements with insulin manufacturers. Others continue to pursue their cases through trial.
The insulin lawsuit is a different beast from the GLP-1 litigation. It’s about economics, not side effects. If you rationed insulin, skipped doses, or went into medical debt because of high prices, you may have a claim.
Key Takeaway: Eli Lilly faces product-specific lawsuits across Mounjaro, Zepbound, and insulin, each with distinct legal theories ranging from failure to warn to price manipulation.
Eli Lilly Drug Pricing Lawsuit
The Eli Lilly drug pricing lawsuit focuses on the company’s broader pattern of setting high list prices and working with pharmacy benefit managers to maintain those prices. This goes beyond just insulin.
Drug pricing lawsuits allege a scheme that works like this: the manufacturer sets a high list price, the PBM negotiates a “rebate” behind closed doors, and the patient still pays based on the inflated list price. Everyone profits except the person who actually needs the medicine.
The FTC has taken an active interest in PBM practices. In 2024 and 2025, the agency issued reports and took enforcement actions against the largest PBMs in the country.
For Eli Lilly specifically, pricing lawsuits argue:
- The company set artificially high wholesale acquisition costs
- Rebate agreements with PBMs kept shelf prices elevated
- Patients with high-deductible plans bore the worst financial burden
- The pricing structure violated consumer protection laws in multiple states
These cases differ from the side effects litigation. You don’t need a physical injury to file a drug pricing claim. Financial harm alone can be enough.
If you paid out of pocket for any Eli Lilly medication at an inflated price, you may qualify. This includes patients who had insurance but still faced steep copays or coinsurance charges.
Eli Lilly Side Effects Lawsuit
The Eli Lilly side effects lawsuit covers a range of adverse reactions linked to the company’s GLP-1 drugs. These reactions go far beyond the typical nausea and vomiting listed on the label.
Plaintiffs report severe and sometimes permanent injuries. The core argument is that Eli Lilly’s warning labels were not specific enough about the severity and duration of certain side effects.
Side effects at the center of the litigation include:
- Gastroparesis (stomach paralysis): food stays in the stomach for abnormally long periods
- Pancreatitis: painful inflammation of the pancreas
- Bowel obstruction: blockage in the intestines requiring emergency surgery
- Gallbladder disease: including gallstones requiring removal
- Ileus: a condition where the intestines stop moving food and waste
- Severe vomiting: episodes lasting days or weeks, sometimes requiring hospitalization
- Kidney injury: linked to severe dehydration from persistent vomiting
| Side Effect | Severity Level | Typical Outcome |
|---|---|---|
| Gastroparesis | Severe | Chronic condition, possible feeding tube |
| Pancreatitis | Severe | Hospitalization, potential organ damage |
| Bowel Obstruction | Emergency | Surgical intervention |
| Gallbladder Disease | Moderate to Severe | Surgical removal |
| Ileus | Severe | Hospitalization |
The FDA has updated the labels for GLP-1 drugs several times. But plaintiffs argue these updates came too late and still don’t go far enough.
Internal company documents could reveal what Eli Lilly knew and when. That’s a big part of what the discovery phase in MDL 3094 is working to uncover.
Eli Lilly Gastroparesis Lawsuit
The Eli Lilly gastroparesis lawsuit is one of the strongest injury categories within the broader GLP-1 litigation. Gastroparesis means the stomach muscles stop working properly, causing food to sit undigested for hours or even days.
This condition can be debilitating. Patients with gastroparesis experience severe nausea, vomiting, abdominal pain, malnutrition, and dramatic weight loss. In serious cases, patients need feeding tubes to survive.
GLP-1 drugs like Mounjaro and Zepbound work by slowing gastric emptying. That’s actually part of how they help with weight loss. The problem is that for some patients, the slowing goes too far and becomes permanent.
Studies published in medical journals have drawn a connection between GLP-1 use and gastroparesis. A 2023 study in the Journal of the American Medical Association found GLP-1 users had a significantly elevated risk of stomach paralysis compared to non-users.
Here’s what makes gastroparesis claims especially strong:
- Clear mechanism: The drug’s intended function (slowing digestion) directly relates to the injury
- Documented cases: FAERS data shows thousands of gastroparesis reports
- Life-altering impact: Many patients cannot eat normally, possibly for the rest of their lives
- Label gaps: Early labels did not mention gastroparesis by name
If you were diagnosed with gastroparesis during or after taking a Eli Lilly GLP-1 drug, your claim sits in the highest injury tier. These cases are likely to see the largest individual payouts.
Key Takeaway: Gastroparesis claims represent the most serious injury category in the Eli Lilly litigation, with a direct link between the drug’s mechanism and the harm caused.
Eli Lilly Compounding Pharmacy Lawsuit
The Eli Lilly compounding pharmacy lawsuit is a different kind of legal battle. Here, Eli Lilly is the plaintiff, not the defendant. The company has sued compounding pharmacies that produce cheaper versions of tirzepatide.
Compounding pharmacies filled the gap when Mounjaro and Zepbound faced shortages. They legally created compounded tirzepatide at a fraction of the cost. A month’s supply from a compounder could cost $200 to $400 compared to over $1,000 for the brand-name drug.
Eli Lilly argues these compounding pharmacies are now operating outside FDA rules. The company says some are selling copies of tirzepatide even after the FDA declared the shortage resolved in late 2024.
This matters to consumers for several reasons:
- Access: If compounders lose, patients lose a cheaper alternative
- Safety: Eli Lilly claims some compounded versions are not bioequivalent
- Pricing: Without compounding competition, Eli Lilly controls the market price
- Legal precedent: The outcome could affect all compounded GLP-1 drugs
Some patients have filed their own suits, arguing they were harmed by poorly made compounded tirzepatide. Others support the compounders, saying Eli Lilly is using litigation to crush affordable competition.
| Perspective | Eli Lilly’s Argument | Compounders’ Argument |
|---|---|---|
| Safety | Compounded versions are unregulated | Products meet USP standards |
| Legality | Shortage is over, compounding should stop | FDA rules allow continued compounding |
| Access | Patients should use FDA-approved drugs | Patients deserve affordable options |
| Motive | Patient safety | Protecting monopoly pricing |
This is one of the most watched pharmaceutical disputes of 2026. The outcome will directly affect what millions of patients pay for their medication.
Eli Lilly Lawsuit Settlement
An Eli Lilly lawsuit settlement has not yet been reached in the GLP-1 side effects litigation as of early 2026. The cases are still in the pretrial phase, and no global settlement offer is on the table.
That doesn’t mean it won’t happen. In fact, the litigation trajectory strongly suggests settlement is the likely endgame. Most pharmaceutical mass torts settle before or shortly after bellwether trials.
Here’s how the settlement process typically works in cases like this:
- Discovery wraps up: Both sides exchange evidence and expert reports
- Bellwether trials begin: A handful of cases go to a jury
- Jury verdicts come in: These signal the strength of each side’s arguments
- Settlement negotiations open: The company calculates its total exposure
- Global settlement announced: A fund is created to pay all qualifying claimants
For the insulin pricing cases, some settlements already exist. Eli Lilly agreed to cap insulin prices and contribute to state-level settlement funds. But the amounts vary widely by state.
| Settlement Track | Status (2026) | Expected Timeline |
|---|---|---|
| GLP-1 Side Effects (MDL 3094) | Pretrial phase | Settlement talks possible late 2026 or 2027 |
| Insulin Pricing (Federal) | Partially settled | Ongoing distributions |
| Insulin Pricing (State AG) | Mixed | State by state |
| Compounding Dispute | Active litigation | No settlement expected soon |
If you’ve already filed a claim, patience is required. These things take time. But the gears are turning, and 2026 could be the year real settlement numbers start emerging.
Eli Lilly Lawsuit Payout
Eli Lilly lawsuit payouts have not been finalized for the GLP-1 injury cases, but legal experts have projected ranges based on comparable pharmaceutical mass torts. Individual payouts will depend heavily on the type and severity of injury.
Think of it like a tiered system. The worse your injury, the more you could receive. Someone hospitalized once for severe vomiting won’t get the same amount as someone living with permanent gastroparesis.
Here are projected payout ranges based on injury tier:
| Injury Tier | Description | Estimated Payout Range |
|---|---|---|
| Tier 1 (Highest) | Gastroparesis, bowel obstruction requiring surgery, organ damage | $150,000 to $500,000+ |
| Tier 2 (High) | Pancreatitis, gallbladder removal, prolonged hospitalization | $75,000 to $200,000 |
| Tier 3 (Moderate) | Severe vomiting/nausea lasting weeks, ER visits, kidney injury | $25,000 to $100,000 |
| Tier 4 (Lower) | Documented side effects with medical treatment but no surgery | $5,000 to $30,000 |
These numbers are estimates. Actual payouts could be higher or lower depending on bellwether trial outcomes and the strength of individual claims.
For insulin pricing cases, payouts to individual consumers tend to be smaller. Past pharmaceutical pricing settlements have produced payments ranging from $25 to $500 per person, depending on how long you overpaid and how much you spent.
Your medical records will be the single most important factor. Keep every document, receipt, and diagnosis record you have. Strong documentation leads to stronger compensation.
Key Takeaway: GLP-1 injury payouts could range from $5,000 to over $500,000 depending on injury severity, while insulin pricing claims will likely produce smaller but still meaningful payments.
Eli Lilly Mounjaro Settlement Amount
The Eli Lilly Mounjaro settlement amount is not yet determined, but early estimates point to a total litigation value in the billions. Individual Mounjaro claimants could receive anywhere from $25,000 to $500,000 or more.
These projections come from analyzing similar pharmaceutical mass torts. The Vioxx settlement totaled $4.85 billion. The Zantac litigation produced substantial individual payouts for cancer claims. The GLP-1 cases could follow a similar pattern.
Several factors will influence how much Mounjaro claimants receive:
- Injury type and severity: Gastroparesis and bowel obstruction cases will receive the most
- Duration of harm: Ongoing or permanent conditions get higher compensation
- Medical expenses: Documented costs for treatment, surgery, and rehabilitation
- Lost income: If you missed work or lost your job due to side effects
- Pain and suffering: Subjective but significant, especially for life-altering injuries
- Strength of evidence: Medical records linking Mounjaro use to the injury
The strongest Mounjaro cases involve patients who can show a clear timeline. They started the drug, developed symptoms, sought medical care, and received a diagnosis consistent with known GLP-1 risks.
If you fall into that category, your case is well-positioned. Attorneys handling Mounjaro claims typically work on contingency, meaning you pay nothing upfront and they take a percentage only if you win.
Who Qualifies for the Eli Lilly Lawsuit
You may qualify for the Eli Lilly lawsuit if you took a Eli Lilly medication and experienced a serious side effect, or if you overpaid for insulin or another Eli Lilly drug. The specific requirements vary by lawsuit type.
For the GLP-1 side effects lawsuit (Mounjaro/Zepbound), you likely qualify if:
- You took Mounjaro or Zepbound (tirzepatide) at any point
- You developed gastroparesis, pancreatitis, bowel obstruction, gallbladder disease, ileus, severe vomiting, or kidney problems
- Your condition required medical treatment, hospitalization, or surgery
- You have medical records documenting both the drug use and the adverse event
For the insulin pricing lawsuit, you likely qualify if:
- You purchased Humalog, Humulin, or another Eli Lilly insulin product
- You paid out-of-pocket costs above $35 per month before the price cap
- You rationed, skipped doses, or went into debt because of insulin costs
- You can document your purchase history
| Qualification Factor | GLP-1 Side Effects | Insulin Pricing |
|---|---|---|
| Drug Used | Mounjaro or Zepbound | Humalog or Humulin |
| Harm Required | Physical injury | Financial harm |
| Medical Records Needed | Yes, critical | Purchase records helpful |
| Time Period | 2022 to present | 2001 to 2023 |
| Geographic Requirement | U.S. residents | U.S. residents |
You don’t need to have been the person who purchased the drug. Family members who experienced harm or bore the financial burden may qualify too.
How to File an Eli Lilly Lawsuit
Filing an Eli Lilly lawsuit starts with contacting an attorney who handles pharmaceutical litigation. Most law firms offer free case evaluations and work on contingency, so there’s no cost to you unless you win.
Here’s the step-by-step process:
Step 1: Gather Your Records
Collect all medical records showing you were prescribed and took a Eli Lilly drug. Get records of any side effects, ER visits, hospitalizations, and diagnoses.
Step 2: Contact a Law Firm
Reach out to a firm experienced in GLP-1 or pharmaceutical mass tort litigation. They’ll review your case for free.
Step 3: Complete a Plaintiff Fact Sheet
Your attorney will help you fill out a detailed questionnaire about your drug use, medical history, and injuries. This form is required for MDL cases.
Step 4: Your Case Gets Filed
The attorney files your individual complaint. If it’s a GLP-1 case, it gets transferred to MDL 3094 in the Eastern District of Pennsylvania.
Step 5: Wait for the Process to Play Out
After filing, your case enters the pretrial process. Discovery, bellwether selection, and potential settlement negotiations happen at the MDL level.
Quick facts about filing:
- Cost to file: $0 upfront with contingency attorneys
- Attorney fees: Typically 33% to 40% of your settlement
- Time to file: Varies by state, but sooner is better
- Where to file: Your attorney handles the jurisdiction logistics
Don’t wait too long. Statutes of limitations apply to every lawsuit. Once the deadline passes, you lose the right to file permanently.
Key Takeaway: Filing is free with a contingency attorney, and the process starts with gathering your medical records and getting a free case evaluation.
Eli Lilly Lawsuit Deadline 2026
The Eli Lilly lawsuit deadline in 2026 depends on your state’s statute of limitations and the type of claim you’re filing. There is no single nationwide deadline.
For personal injury claims (side effects cases), most states give you two to three years from the date you discovered the injury or should have discovered it. This is called the “discovery rule.”
For drug pricing claims, state consumer protection statutes typically allow three to six years from the date of the overcharge.
| State Examples | Personal Injury Deadline | Consumer Protection Deadline |
|---|---|---|
| California | 2 years from discovery | 4 years |
| Texas | 2 years from discovery | 4 years |
| New York | 3 years from discovery | 6 years |
| Florida | 2 years from discovery | 4 years |
| Illinois | 2 years from discovery | 5 years |
If you first experienced side effects in 2024, your window could close as early as 2026 in some states. That makes this year a genuine deadline for many potential claimants.
Do not assume you have plenty of time. The statute of limitations runs even if you don’t know about the lawsuit. Once it expires, no attorney can help you.
Getting a free evaluation now costs nothing and protects your rights. Even if you’re unsure about filing, an initial consultation preserves your options.
Frequently Asked Questions
Is there a class action lawsuit against Eli Lilly in 2026?
Yes, Eli Lilly faces class action claims related to insulin pricing.
The GLP-1 side effects cases (Mounjaro and Zepbound) are individual lawsuits consolidated in MDL 3094.
Both types of litigation are active in 2026.
How much money can I get from the Eli Lilly lawsuit?
Payouts for GLP-1 injury claims are estimated between $5,000 and $500,000 or more, depending on injury severity.
Insulin pricing claims may produce smaller payments, typically $25 to $500 per person.
No final settlement amounts have been announced yet.
What are the side effects covered in the Eli Lilly Mounjaro lawsuit?
The lawsuit covers gastroparesis, pancreatitis, bowel obstruction, gallbladder disease, ileus, severe vomiting, and kidney injury.
These are serious conditions that required medical treatment, hospitalization, or surgery.
Mild nausea alone typically does not qualify for a claim.
What is the deadline to file an Eli Lilly lawsuit in 2026?
The deadline varies by state, with most states allowing two to three years from the date of injury discovery.
Some claimants who experienced side effects in 2024 face deadlines in 2026.
Contact an attorney now to confirm your state’s specific statute of limitations.
Do I need a lawyer to join the Eli Lilly lawsuit?
You do not technically need a lawyer, but handling a pharmaceutical mass tort case alone is extremely difficult.
Most attorneys take these cases on contingency, meaning you pay nothing upfront.
Having legal representation significantly increases your chances of receiving fair compensation.
This is a pivotal year for the Eli Lilly litigation. Whether you’re dealing with side effects from Mounjaro or Zepbound, or you overpaid for insulin, the time to act is now.
Check your eligibility by contacting a pharmaceutical litigation attorney for a free case review. Keep your medical records organized and accessible.
Don’t let a deadline pass you by. Your claim has value, and 2026 may be the year it starts paying out.
